Navigation Links
Statement From Volcano Corporation on Latest St. Jude Lawsuit
Date:5/26/2011

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) today issued the following statement:

Earlier this year, the Massachusetts Superior Court rejected claims by LightLab Imaging, a wholly-owned subsidiary of St. Jude Medical, that Volcano Corporation and its wholly-owned subsidiary, Axsun Technologies, misappropriated LightLab's confidential information in connection for use in the development of Volcano's Optical Coherence Tomography (OCT) System.  Now LightLab is bringing similar claims in a new lawsuit filed May 24, 2011 in a Delaware court, in which LightLab alleges that Axsun is somehow wrongfully participating in Volcano's development of alternative OCT light sources, including initiatives underway with third parties.  

Volcano denies these unfounded allegations.  Volcano firmly believes that this latest lawsuit has no merit, and looks forward to the opportunity to proving so in court.  

About Volcano Corporation

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive.  Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements.  Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies, product development milestones, outcome of ongoing litigation, the impact and benefits of market developments, dependence upon third parties, product introductions, unexpected new data, safety and technical issues, market conditions, and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 2016 ReportsnReports.com adds Global ... Devices of its online business intelligence library. This ... current state of the Titrator industry. The report ... definitions, classifications, Specifications, applications and industry chain structure. ... Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, ...
(Date:5/20/2016)... India , May 20, 2016 ... - Pipeline Review, H1 2016" market research report ... Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ...
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance ... summit on September 15 and 16, 2016 in San Diego, CA. The two ... bearers will be one of the largest gatherings of medical device companies, suppliers, professionals ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley ... worldwide for people who are blind or visually impaired, announces the election of ... President Charles E. Young. Hadley’s Board of Trustees retained Morris & Berger, a ...
(Date:5/23/2016)... ... 23, 2016 , ... Octo Consulting Group, a leading provider of innovative information ... announce they have recently won two awards from AFCEA International. Octo was selected ... Year. Additionally, Octo VP of Civilian Affairs, Naina Leo, was named a winner of ...
(Date:5/23/2016)... , ... May 23, 2016 , ... VitreosHealth is presenting ... 10, 2016 from 11:00 AM – 12:00 PM ET. To register, click ... start a proactive outreach program built on Big Data with a new predictive and ...
Breaking Medicine News(10 mins):